New drug extends life in women with advanced ovarian cancer

November 5, 2013, Cancer Research UK

Women with ovarian cancer that has returned after previous treatment had their life extended by almost three months after treatment with a drug called Cediranib, according to trial results presented today at the National Cancer Research (NCRI) Cancer Conference in Liverpool.

The Cancer Research UK-funded phase III clinical trial found that patients given Cediranib with chemotherapy gained an extra 3.2 months before their cancer progressed (from 9.4 to 12.6 months). And, on average, women survived for an extra three months, from 17.6 to 20.3 months compared to women only given chemotherapy.

Professor Jonathan Ledermann, chief investigator based at the Cancer Research UK UCL centre, said: "While the increase in survival may seem modest, this is a significant finding for women with advanced ovarian cancer. Cediranib is the first of its kind that has been shown to delay tumour progression and improve overall survival in ovarian cancer that has returned."

Cediranib, which is taken in pill form, is a type of drug called a tyrosine kinase inhibitor that stops tumours from being able to make new blood vessels that are essential for cancer growth.

In women whose ovarian cancer has returned and treated with the standard platinum-based chemotherapy it normally takes eight to nine months before the cancer starts to grow again. But when treated with Crdiranib this was extended to over 12 months.

A total of 456 patients whose ovarian cancer had returned were enrolled in the trial at 63 centres from the UK, Canada, Australia and Spain. They were randomised to receive platinum-based chemotherapy together with a placebo, or 20 mg a day of Cediranib during chemotherapy followed by placebo for 18 months, or 20 mg a day of Cediranib during chemotherapy followed by Cediranib as a maintenance treatment.

Professor Matt Seymour, NCRI clinical research director, said: "These results are very encouraging. They show clearly that this new drug, which works in a totally different way to conventional chemotherapy, can significantly help patients with ovarian cancer. The average benefit is modest – around 3 months – but worthwhile; and in the future it may be possible to identify who gains most from this drug.

"It is also important to remember that, like most cancer treatment, progress in ovarian cancer is incremental. Over time, the small benefits from many different research programmes like this add together to make a huge difference to patients' lives."

Each year around 7,000 women are diagnosed with ovarian cancer in the UK and despite ovarian cancer survival almost doubling in the last 30 years the survival rate remains at 43 per cent.

Kate Law, Cancer Research UK's director of , said: "Ovarian cancer can be hard to diagnose early and treat successfully, so it's significant that this study found a drug that can slow tumour growth following treatment. We urgently need better treatments for and it's promising that this appears to also give valuable extra months of life. It's only through research like this that we can beat cancer sooner."

The ICON 6 trial was co-ordinated by the MRC Clinical trials unit at UCL and was also funded by AstraZeneca.

Explore further: Biological therapy with cediranib improves survival in women with recurrent ovarian cancer

More information: conference.ncri.org.uk/abstrac … 3/abstracts/LB80.htm

Related Stories

Biological therapy with cediranib improves survival in women with recurrent ovarian cancer

September 30, 2013
Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European ...

New research shows 'DNA tags' could guide treatment for advanced ovarian cancer

October 15, 2013
A Cancer Research UK study has identified chemical 'tags' on DNA in patients' tumours that could help doctors decide the type of chemotherapy women with advanced ovarian cancer should receive, according to a new paper published ...

Targeted treatment plus chemotherapy could benefit women with ovarian cancer

October 11, 2013
Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows.

Drug can delay ovarian cancer relapses: study

June 1, 2013
A drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study released Saturday found.

Drug cocktail boosts ovarian cancer survival time

June 2, 2012
A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.

New ovarian cancer treatment succeeds in the lab

October 17, 2013
In a study to be published today in Scientific Reports, researchers from the Florida International University Herbert Wertheim College of Medicine and the FIU College of Engineering and Computing describe what could be a ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.